The Symptoms Of Multiple Sclerosis Blog

Information and Resources on Multiple Sclerosis and its signs and symptoms!
English flagItalian flagKorean flagChinese (Simplified) flagPortuguese flagGerman flagFrench flagSpanish flagJapanese flagArabic flagRussian flagGreek flagDutch flagBulgarian flagCzech flagCroat flagDanish flagFinnish flagHindi flagPolish flagRumanian flagSwedish flagNorwegian flag
By N2H

Teva Enrolls Patients For A Second Large Global Phase III Trial Of Oral Laquinimod July 21, 2008

Filed under: MS — The Symptoms Of Multiple Sclerosis Blog @ 7:00 am

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced that patients are being enrolled for the BRAVO Phase III pivotal trial. BRAVO is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex®.

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • StumbleUpon
  • Technorati


add to del.icio.usPrint This Post Print This Post

Leave a Reply